KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) EBT Margin (2016 - 2025)

Historic EBT Margin for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to 81.93%.

  • Ionis Pharmaceuticals' EBT Margin rose 257600.0% to 81.93% in Q3 2025 from the same period last year, while for Sep 2025 it was 32.71%, marking a year-over-year increase of 116900.0%. This contributed to the annual value of 65.34% for FY2024, which is 228400.0% down from last year.
  • Per Ionis Pharmaceuticals' latest filing, its EBT Margin stood at 81.93% for Q3 2025, which was up 257600.0% from 44.44% recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' EBT Margin ranged from a high of 50.93% in Q4 2021 and a low of 119.44% during Q1 2024
  • Its 5-year average for EBT Margin is 53.51%, with a median of 62.94% in 2021.
  • Its EBT Margin has fluctuated over the past 5 years, first soared by 2088400bps in 2021, then tumbled by -804500bps in 2022.
  • Over the past 5 years, Ionis Pharmaceuticals' EBT Margin (Quarter) stood at 50.93% in 2021, then tumbled by -158bps to 29.52% in 2022, then soared by 96bps to 1.08% in 2023, then crashed by -4295bps to 47.53% in 2024, then plummeted by -72bps to 81.93% in 2025.
  • Its EBT Margin stands at 81.93% for Q3 2025, versus 44.44% for Q2 2025 and 111.56% for Q1 2025.